Unlabelled: Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients but has been difficult to capture in laboratory models. Here we present a pre-clinical system that recapitulates acquired cross-resistance in SCLC, developed from 51 patient-derived xenografts (PDXs). Each model was tested for sensitivity to three clinical regimens: cisplatin plus etoposide, olaparib plus temozolomide, and topotecan. These functional profiles captured hallmark clinical features, such as the emergence of treatment-refractory disease after early relapse. Serially derived PDX models from the same patient revealed that cross-resistance was acquired through a amplification on extrachromosomal DNA (ecDNA). Genomic and transcriptional profiles of the full PDX panel revealed that this was not unique to one patient, as paralog amplifications on ecDNAs were recurrent among cross-resistant models derived from patients after relapse. We conclude that ecDNAs with paralogs are recurrent drivers of cross-resistance in SCLC.
Significance: SCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population of PDX models to discover that amplifications of paralogs on ecDNA are recurrent drivers of acquired cross-resistance in SCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327110 | PMC |
| http://dx.doi.org/10.1101/2023.06.23.546278 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance.
Virus Evol
November 2024
Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1043, Leuven 3000, Belgium.
The widespread use of antivirals in immunocompromised individuals has led to frequent occurrences of drug-resistant herpes simplex virus 1 (HSV-1) infections. Current antivirals target the viral DNA polymerase (DP), resulting in cross-resistance patterns that emphasize the need for novel treatment strategies. In this study, we assessed whether combining antivirals with different targets affects drug resistance emergence by passaging wild-type HSV-1 under increasing concentrations of acyclovir (ACV), foscarnet (phosphonoformic acid, PFA), or the helicase-primase inhibitor pritelivir (PTV), individually or in combination (ACV + PTV or PFA + PTV).
View Article and Find Full Text PDFKRAS mutations are frequent in various human cancers. The development of selective inhibitors targeting KRAS mutations has opened a new era for targeted therapy. However, intrinsic and acquired resistance to these inhibitors remains a major challenge.
View Article and Find Full Text PDFRole of the two-component system AmgRS in early resistance of to cinnamaldehyde.
Microbiol Spectr
December 2024
UMR CNRS 6249 Chrono-Environnement, UFR Santé, Université Bourgogne Franche-Comté, Besançon, France.
Exposure of to cinnamaldehyde (CNA), a natural electrophilic antimicrobial often used as self-medication to treat mild infections, triggers overproduction of the MexAB-OprM efflux system, leading to multidrug resistance. In this study, we demonstrate that CNA exposure induces expression of genes regulated by the two-component system AmgRS. AmgRS activates MexAB-OprM production, independent of repressors MexR and NalD.
View Article and Find Full Text PDFCancers exhibit a remarkable ability to develop resistance to a range of treatments, often resulting in relapse following first-line therapies and significantly worse outcomes for subsequent treatments. While our understanding of the mechanisms and dynamics of the emergence of resistance during cancer therapy continues to advance, many questions remain about which treatment strategies can minimize the probability that resistance will evolve, thereby improving long-term patient outcomes. In this study, we present an evolutionary simulation model of a clonal population of cells that can acquire resistance mutations to one or more treatments.
View Article and Find Full Text PDFThe intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways.
Front Oncol
November 2024
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
Article Synopsis
- Endocrine therapy targeting the estrogen receptor alpha (ERα) has been successful for treating estrogen receptor positive (ER+) breast cancer since the 1970s, but most patients eventually develop resistance, particularly in metastatic cases.
- Resistance often stems from genetic changes in the estrogen receptor, the MAP kinase pathway, or transcription factors, with mutations in HER2 leading to total resistance against multiple therapies.
- Recent studies suggest a link between endocrine-resistant tumors and the HER2-low subtype, indicating a need for more research into the signaling networks in HER2-low tumors that could be targeted to overcome resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!